EGFR and glioblastoma: They observed that besides the mutations in signature oncogenes of glioblastoma (e.g., EGFR and phosphatidylinositol 3-kinase (PI3K)), more than 40% of patients had mutations among the chromatin-modifier genes, which play a major role in chromatin organization in glioblastoma pathology [52,53].